Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cx601 for complex perianal fistulas in Crohn's disease
NCT03279081Phase 3Completed
- Sponsor
- TiGenix
- Start
- Sep 2017
- Primary completion
- Jan 2023
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease and perianal fistula comparing Cx601 with Placebo (2 arms). Primary endpoint: Combined Remission at 24 weeks. Started Sep 2017; status: completed.
02
Drugs
darvadstrocel
03
Conditions
Crohn's diseaseperianal fistula
Beyond the preview
Go deeper on NCT03279081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03279081.